Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

Suppr

超能文献

作者信息

Männistö P T, Kaakkola S

机构信息

Department of Pharmacology and Toxicology, University of Helsinki, Finland.

出版信息

Pharmacol Toxicol. 1990 May;66(5):317-23. doi: 10.1111/j.1600-0773.1990.tb00756.x.

DOI:10.1111/j.1600-0773.1990.tb00756.x

PMID:2196554

Abstract

摘要

相似文献

Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

Pharmacol Toxicol. 1990 May;66(5):317-23. doi: 10.1111/j.1600-0773.1990.tb00756.x.

Catechol-O-methyltransferase and Parkinson's disease.儿茶酚-O-甲基转移酶与帕金森病

Acta Med Okayama. 2002 Feb;56(1):1-6. doi: 10.18926/AMO/31725.

Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.儿茶酚-O-甲基转移酶（COMT）抑制剂的药物化学及其治疗用途。

J Med Chem. 2014 Nov 13;57(21):8692-717. doi: 10.1021/jm500572b. Epub 2014 Sep 2.

First COMT inhibitor approved for Parkinson's disease.

Am J Health Syst Pharm. 1998 Mar 15;55(6):524, 526. doi: 10.1093/ajhp/55.6.524.

Tolcapone: COMT inhibition for the treatment of Parkinson's disease.

Neurology. 1998 May;50(5 Suppl 5):S1-2. doi: 10.1212/wnl.50.5_suppl_5.s1.

Comt inhibition in the treatment of Parkinson's disease: neuroprotection and future perspectives.儿茶酚-O-甲基转移酶抑制在帕金森病治疗中的作用：神经保护及未来展望

Adv Exp Med Biol. 2004;541:75-90. doi: 10.1007/978-1-4419-8969-7_5.

Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.罗匹尼罗40-7592，一种儿茶酚-O-甲基转移酶（COMT）抑制剂，联合左旋多巴治疗帕金森病。

Lancet. 1993 Jun 19;341(8860):1605. doi: 10.1016/0140-6736(93)90750-b.

Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.奥匹卡朋对帕金森病患者左旋多巴药代动力学、儿茶酚-O-甲基转移酶活性及运动波动的影响。

Eur J Neurol. 2015 May;22(5):815-25, e56. doi: 10.1111/ene.12666. Epub 2015 Feb 4.

Impact of oral COMT-inhibitors on gut microbiota and short chain fatty acids in Parkinson's disease.口服儿茶酚-O-甲基转移酶抑制剂对帕金森病肠道微生物群和短链脂肪酸的影响

Parkinsonism Relat Disord. 2020 Jan;70:20-22. doi: 10.1016/j.parkreldis.2019.11.020. Epub 2019 Nov 25.

Catechol-O-methyltransferase inhibitors in Parkinson's disease.帕金森病中的儿茶酚-O-甲基转移酶抑制剂

Lancet. 1998 Jun 27;351(9120):1966. doi: 10.1016/S0140-6736(05)78660-8.

引用本文的文献

Entacapone scavenges peroxynitrite and protects against kidney and liver injuries induced by renal ischemia/reperfusion in rats.恩他卡朋清除过氧亚硝酸盐，防止肾缺血/再灌注引起的大鼠肾和肝损伤。

Int Urol Nephrol. 2021 Aug;53(8):1713-1721. doi: 10.1007/s11255-021-02827-5. Epub 2021 Mar 6.

Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.一项随机试验表明，增加卡比多巴-左旋多巴和恩他卡朋的剂量可改善“关期”。

Neurology. 2019 Mar 26;92(13):e1487-e1496. doi: 10.1212/WNL.0000000000007173. Epub 2019 Mar 1.

[Pharmacological treatment of motor symptoms in Parkinson's diseases].[帕金森病运动症状的药物治疗]

Nervenarzt. 2017 Apr;88(4):373-382. doi: 10.1007/s00115-017-0309-z.

Clinical Potential of Catechol-OMethyltransferase (COMT) Inhibitors as Adjuvants in Parkinson's Disease.儿茶酚-O-甲基转移酶（COMT）抑制剂作为帕金森病辅助治疗的临床潜力。

CNS Drugs. 1994 Mar;1(3):172-9. doi: 10.2165/00023210-199401030-00002.

Comprehensive interrogation of CpG island methylation in the gene encoding COMT, a key estrogen and catecholamine regulator.全面检测编码 COMT 基因中的 CpG 岛甲基化，COMT 是关键的雌激素和儿茶酚胺调节剂。

BMC Med Genomics. 2014 Jan 24;7:5. doi: 10.1186/1755-8794-7-5.

NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.NAD(P)H：醌氧化还原酶1的Arg139Trp和Pro187Ser多态性使雌激素代谢失衡，导致人乳腺上皮细胞中DNA加合物形成。

J Steroid Biochem Mol Biol. 2009 Oct;117(1-3):56-66. doi: 10.1016/j.jsbmb.2009.07.003. Epub 2009 Jul 21.

Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.儿茶酚-O-甲基转移酶及其抑制剂与帕金森病

CNS Drug Rev. 2007 Fall;13(3):352-79. doi: 10.1111/j.1527-3458.2007.00020.x.

The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise.儿茶酚-O-甲基转移酶抑制剂恩他卡朋对运动期间血流动力学和外周儿茶酚胺代谢的影响。

Br J Clin Pharmacol. 1993 Nov;36(5):451-6. doi: 10.1111/j.1365-2125.1993.tb00394.x.

Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.儿茶酚-O-甲基转移酶抑制剂恩他卡朋对华法林稳态药代动力学和药效学的影响。

Br J Clin Pharmacol. 2002 May;53(5):485-91. doi: 10.1046/j.1365-2125.2002.01587.x.

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.儿茶酚-O-甲基转移酶抑制剂在帕金森病中的临床药理学、治疗用途及潜力

Drugs. 2000 Jun;59(6):1233-50. doi: 10.2165/00003495-200059060-00004.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验